High branded cash-pay medication, though Lilly has also pushed direct-pay and savings-card pathways that can materially change out-of-pocket cost for some patients.

Coverage varies sharply by plan and employer policy. Prior authorization and obesity-benefit exclusions remain common.

FDA-approved for adults with BMI of 30 or higher (obesity), or BMI of 27 or higher (overweight) with at least one weight-related comorbidity, when diet and exercise alone have not been enough.

Adults with BMI of 30 or higher (obesity), or BMI of 27 or higher (overweight) with at least one weight-related comorbidity.

The list price is roughly $1,060 per month. Lilly offers a savings card that can reduce the cost to as low as $25 per month for eligible patients with commercial insurance. Self-pay patients can access Zepbound vials through LillyDirect starting at roughly $399 per month. Lilly has been the most aggressive manufacturer on direct-pay pricing in the GLP-1 obesity space.

Titration starts at 2.5 mg and steps up every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg. The full escalation to the highest dose takes roughly 20 weeks. The injection uses a single-dose autoinjector, given once weekly in the thigh, abdomen, or upper arm. Many patients report that gastrointestinal side effects are concentrated in the first 8 to 12 weeks and ease with continued use.

SURMOUNT trial data showed the largest average weight loss of any branded obesity medication at the time and reset the efficacy bar for the category.

SURMOUNT-1 (72 weeks): participants lost an average of 16.0% of body weight at the 5 mg dose, 21.4% at 10 mg, and 22.5% at 15 mg, compared with 2.4% for placebo. At 15 mg, 63% of participants achieved 20% or more weight loss and 78% achieved 15% or more. SURMOUNT-2 (participants with type 2 diabetes): average loss of 12.8% at 10 mg and 14.7% at 15 mg. SURMOUNT-3 and SURMOUNT-4 tested intensive lifestyle intervention and treatment maintenance; both supported the idea that weight loss holds up longer and is larger when tirzepatide is combined with structured behavior change.

Warnings overlap with the GLP-1 class, including GI effects, pancreatitis, gallbladder disease, kidney injury, and boxed warning language related to thyroid C-cell tumors in rodents.

nausea, diarrhea, vomiting, constipation, injection-site reactions

In SURMOUNT-1, nausea occurred in roughly 24-33% of participants depending on dose, diarrhea in 18-25%, vomiting in 7-13%, and constipation in 11-17%. The gastrointestinal profile was generally manageable and concentrated during dose escalation. Discontinuation rates due to adverse events were modest relative to the weight-loss magnitude.

Once-weekly subcutaneous injection with dose escalation from 2.5 mg to maintenance doses up to 15 mg.

Single-dose autoinjector or single-dose vial depending on product format.